{
    "medicine_id": "4ee62a8e8cb3e7f200ae2b27d380bad6287fe982",
    "platform_id": "DB15694",
    "metadata": {
        "name": "Inqovi Tablet film coated",
        "composition": "Cedazuridine",
        "clinical_particulars": {
            "therapeutic_indications": "Cedazuridine in combination with decitabine is indicated for the treatment of myelodysplastic syndromes MDS including MDS with refractory anemia MDS with refractory anemia and ringed sideroblasts MDS with refractory anemia and excess blasts MDS scoring intermediate 1 intermediate 2 or high risk on the International Prognostic Scoring System IPSS and chronic myelomonocytic leukemia CMML L14897",
            "contraindications": {
                "disease": "Cedazuridine administered orally to mice in 7 days on 21 days off cycles for a total of 91 days in doses of 100 300 or 1000 mg kg produced abnormal effects only at the 1000 mg kg dose which is roughly 108 times the recommended dose in humans These effects included abnormal histology of the testes epididymis and ovaries as well as decreased sperm count these effects were reversible following cedazuridine removal",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Cedazuridine is a cytidine deaminase inhibitor that is co administered with hypomethylating agents such as decitabine in order to increase their oral bioavailability A215107 A215112 A215117 A215127 In combination with hypomethylating agents cedazuridine may cause myelosuppression and embryo fetal toxicity and should be administered with appropriate monitoring L14897",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}